GSK Buyout Turns Volatile RAPT Into Food Allergy Cash-Out Story

Simply Wall St.01-24

GSK has signed a definitive agreement to acquire RAPT Therapeutics (NasdaqGM:RAPT). The deal centers on ozureprubart, a long acting anti-IgE antibody in Phase IIb trials for food allergy prophylaxis. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605235195?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-24 14:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605235195","market":"us","top_or_hot":-1,"title":"GSK Buyout Turns Volatile RAPT Into Food Allergy Cash-Out Story","media":"Simply Wall St.","content":"<div>\n<p>GSK has signed a definitive agreement to acquire RAPT Therapeutics (NasdaqGM:RAPT). The deal centers on ozureprubart, a long acting anti-IgE antibody in Phase IIb trials for food allergy prophylaxis. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapt/rapt-therapeutics/news/gsk-buyout-turns-volatile-rapt-into-food-allergy-cash-out-st\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Buyout Turns Volatile RAPT Into Food Allergy Cash-Out Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Buyout Turns Volatile RAPT Into Food Allergy Cash-Out Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-24 14:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapt/rapt-therapeutics/news/gsk-buyout-turns-volatile-rapt-into-food-allergy-cash-out-st><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GSK has signed a definitive agreement to acquire RAPT Therapeutics (NasdaqGM:RAPT). The deal centers on ozureprubart, a long acting anti-IgE antibody in Phase IIb trials for food allergy prophylaxis. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapt/rapt-therapeutics/news/gsk-buyout-turns-volatile-rapt-into-food-allergy-cash-out-st\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1829250122.USD","symbol_name":"高盛欧洲核心股票组合Acc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapt/rapt-therapeutics/news/gsk-buyout-turns-volatile-rapt-into-food-allergy-cash-out-st","article_id":"2605235195","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapt/rapt-therapeutics/news/gsk-buyout-turns-volatile-rapt-into-food-allergy-cash-out-st","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605235195","pubTimestamp":1769236409,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"GSK has signed a definitive agreement to acquire RAPT Therapeutics (NasdaqGM:RAPT).\nThe deal centers on ozureprubart, a long acting anti-IgE antibody in Phase IIb trials for food allergy prophylaxis.\nThe transaction brings a food allergy candidate into GSK’s immunology and inflammation portfolio.\n\nRAPT Therapeutics, trading at $57.63, has recently seen very large 1 year returns and strong short term moves, with the share price up 64.2% over the past week and 60.8% over the past month. Year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4588":"碎股","GSK.UK":"葛兰素史克","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","GSK":"葛兰素史克","BK4007":"制药","RAPT":"RAPT Therapeutics, Inc."},"translate_title":"葛兰素史克收购将不稳定的注意力变成了食物过敏套现故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.5,"RAPT":1.5,"GSK.UK":0.6},"content_text":"GSK has signed a definitive agreement to acquire RAPT Therapeutics (NasdaqGM:RAPT). The deal centers on ozureprubart, a long acting anti-IgE antibody in Phase IIb trials for food allergy prophylaxis. The transaction brings a food allergy candidate into GSK’s immunology and inflammation portfolio.  RAPT Therapeutics, trading at $57.63, has recently seen very large 1 year returns and strong short term moves, with the share price up 64.2% over the past week and 60.8% over the past month. Year to date, the stock is up 80.9%, although 3 year and 5 year returns show sizeable declines, which highlights how volatile the journey has been for investors in NasdaqGM:RAPT. With GSK moving to acquire the company, attention is likely to stay on ozureprubart and how it might fit into broader efforts to address food allergy risk. For current and prospective investors, the main areas of focus are deal completion, timing, and how the combined group may prioritize this asset within its wider immunology pipeline. Stay updated on the most important news stories for RAPT Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on RAPT Therapeutics. NasdaqGM:RAPT 1-Year Stock Price Chart Why RAPT Therapeutics could be great value The agreed takeout price of $58 per share, valuing RAPT at about $2.2b, effectively caps near term upside for existing shareholders and shifts the focus to deal completion rather than standalone prospects for ozureprubart. The sizable premium to the pre announcement price, along with a cash tender offer and second step merger structure, typically anchors trading close to the offer level while investors weigh deal risk, the timeline into the expected Q1 2026 close, and the opportunity cost of holding versus redeploying capital. AdvertisementRAPT Therapeutics Narrative: From high volatility to takeout story This acquisition news reframes RAPT from a volatile clinical stage biotech with sizeable drawdowns over 3 and 5 years into a cash realization story linked to GSK’s tender offer. For investors who previously focused on the long runway and clinical risk around ozureprubart, the narrative now leans more toward merger arbitrage considerations, such as the probability of closing, regulatory review, and any competing interest that could influence the final outcome. Risks and rewards for RAPT shareholders  ⚠️ Execution risk around the tender offer and required regulatory approvals, including Hart Scott Rodino, could affect timing or completion. ⚠️ RAPT remains a pre revenue company, with less than US$1m in sales and earnings forecast to decline over the next 3 years, which underlines dependence on this transaction. ⚠️ History of high share price volatility and past shareholder dilution highlight the underlying risk profile if the deal were to fall through. 🎁 The all cash offer at $58 per share provides price visibility for holders who previously faced significant uncertainty tied to clinical and funding outcomes.  What to watch next From here, the key watchpoints are tender offer progress, any regulatory feedback, and whether new information on ozureprubart’s Phase IIb program affects market confidence in deal completion. You can stay on top of how investors interpret those signals by following the latest community narratives in this dedicated feed.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605235195","isCrawlerRequest":true}